尿液 pH 值对美西律消除的影响。
The influence of urinary pH on the elimination of mexiletine.
机构信息
Department of Clinical Pharmacology, St Bartholomew's Hospital, London.
出版信息
Br J Clin Pharmacol. 1974 Jun;1(3):229-32. doi: 10.1111/j.1365-2125.1974.tb00241.x.
Abstract
1 The plasma elimination half-life of mexiletine was measured in four subjects when the urine was rendered (a) acidic and (b) alkaline. 2 Urinary acidification (pH 5.0) was associated with a plasma elimination half-life of 2.8 h and 57.5% of the intravenous dose was excreted in the urine within 48 hours. When the urine was alkaline (pH 8.0) the half-life increased to 8.6 h with negligible amounts of drug appearing in the urine. 3 Urinary pH varies widely in cardiac patients and should be controlled or monitored to provide better therapeutic precision with mexiletine.
摘要
当尿液被酸化（a）和碱化（b）时，四名受试者的美西律血浆消除半衰期被测量。
尿液酸化（pH5.0）与 2.8 小时的血浆消除半衰期相关，并且静脉注射剂量的 57.5%在 48 小时内从尿液中排出。当尿液碱化（pH8.0）时，半衰期增加至 8.6 小时，尿液中几乎没有药物出现。
心脏病人的尿液 pH 值变化很大，应加以控制或监测，以提供更好的美西律治疗精度。
相似文献
1
The influence of urinary pH on the elimination of mexiletine.尿液 pH 值对美西律消除的影响。
Br J Clin Pharmacol. 1974 Jun;1(3):229-32. doi: 10.1111/j.1365-2125.1974.tb00241.x.
2
Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.美西律的处置：对尿液酸化和碱化反应的个体差异。
Br J Clin Pharmacol. 1983 Sep;16(3):281-4. doi: 10.1111/j.1365-2125.1983.tb02162.x.
3
Elimination of flecainide as a function of urinary flow rate and pH.氟卡尼的消除与尿流率和pH值的关系。
Eur J Clin Pharmacol. 1991;41(1):61-3. doi: 10.1007/BF00280108.
4
Influence of urinary pH on the pharmacokinetics of cinoxacin in humans and on antibacterial activity in vitro.尿液pH值对西诺沙星在人体内药代动力学及体外抗菌活性的影响。
Antimicrob Agents Chemother. 1982 Mar;21(3):472-80. doi: 10.1128/AAC.21.3.472.
5
The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers.健康志愿者长期服用美西律期间，尿pH值自发变化对美西律血浆浓度及排泄的影响。
Br J Clin Pharmacol. 1979 Oct;8(4):349-52. doi: 10.1111/j.1365-2125.1979.tb04717.x.
6
Influence of urinary pH on pethidine kinetics in healthy volunteer subjects. 2. A study of ten Chinese subjects.尿液pH值对健康志愿者体内哌替啶动力学的影响。2. 对十名中国受试者的研究。
Methods Find Exp Clin Pharmacol. 1987 Jan;9(1):49-54.
7
Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.异喹胍羟化代谢表型对美西律药代动力学的影响。
Eur J Clin Pharmacol. 1993;44(1):63-7. doi: 10.1007/BF00315282.
8
Effect of rifampicin treatment on the kinetics of mexiletine.利福平治疗对美西律动力学的影响。
Eur J Clin Pharmacol. 1982;23(3):261-6. doi: 10.1007/BF00547565.
9
Clinical pharmacokinetics of the newer antiarrhythmic agents.新型抗心律失常药物的临床药代动力学
Clin Pharmacokinet. 1984 Sep-Oct;9(5):375-403. doi: 10.2165/00003088-198409050-00001.
10
Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.美西律的药理学、电生理学及药代动力学
Am Heart J. 1984 May;107(5 Pt 2):1058-65. doi: 10.1016/0002-8703(84)90175-3.
引用本文的文献
1
Identifying organic chemicals not subject to bioaccumulation in air-breathing organisms using predicted partitioning and biotransformation properties.利用预测的分配和生物转化特性来识别空气中呼吸生物不易生物积累的有机化学品。
Integr Environ Assess Manag. 2022 Sep;18(5):1297-1312. doi: 10.1002/ieam.4555. Epub 2021 Dec 16.
2
Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine.机制性 PBPK 模型研究尿液 pH 值对甲基苯丙胺和苯丙胺在肾脏和全身的处置的影响。
J Pharmacol Exp Ther. 2020 Jun;373(3):488-501. doi: 10.1124/jpet.120.264994. Epub 2020 Mar 20.
3
Clinical pharmacokinetics of mexiletine.美西律的临床药代动力学。
Clin Pharmacokinet. 1999 Nov;37(5):361-84. doi: 10.2165/00003088-199937050-00002.
4
Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.异喹胍羟化代谢表型对美西律药代动力学的影响。
Eur J Clin Pharmacol. 1993;44(1):63-7. doi: 10.1007/BF00315282.
5
Effect of rifampicin treatment on the kinetics of mexiletine.利福平治疗对美西律动力学的影响。
Eur J Clin Pharmacol. 1982;23(3):261-6. doi: 10.1007/BF00547565.
6
Cirrhosis of the liver markedly impairs the elimination of mexiletine.肝硬化会显著损害美西律的消除。
Eur J Clin Pharmacol. 1986;30(1):83-8. doi: 10.1007/BF00614201.
7
[Treatment with mexiletine. Clinical and pharmacokinetic studies].[美西律治疗。临床及药代动力学研究]
Klin Wochenschr. 1988 Jun 1;66(11):475-81. doi: 10.1007/BF01876168.
8
Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.美西律。对其药效学和药代动力学特性以及在心律失常治疗中的治疗用途的综述。
Drugs. 1990 Sep;40(3):374-411. doi: 10.2165/00003495-199040030-00005.
9
Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.运用药代动力学原理对抗心律失常药物治疗进行实际优化。
Clin Pharmacokinet. 1991 Feb;20(2):151-66. doi: 10.2165/00003088-199120020-00006.
10
Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.美西律：其药理特性及在心律失常治疗中的疗效综述。
Drugs. 1979 Mar;17(3):161-81. doi: 10.2165/00003495-197917030-00003.
本文引用的文献
1
Studies in diurnal variation of water and electrolyte excretion; nocturnal diuresis of water and sodium in congestive cardiac failure and cirrhosis of the liver.水和电解质排泄的昼夜变化研究；充血性心力衰竭和肝硬化患者水和钠的夜间利尿情况。
J Clin Invest. 1951 Nov;30(11):1191-9. doi: 10.1172/JCI102538.
2
INFLUENCE OF URINARY PH ON EXCRETION OF AMPHETAMINE.尿pH值对苯丙胺排泄的影响
Lancet. 1965 Feb 6;1(7380):303. doi: 10.1016/s0140-6736(65)91033-0.
3
RENAL TUBULAR MECHANISMS FOR EXCRETION OF ORGANIC ACIDS AND BASES.有机酸和碱排泄的肾小管机制
Am J Med. 1964 May;36:743-62. doi: 10.1016/0002-9343(64)90183-4.
4
A study of the inverse relationship between pKa and rate of renal excretion of phenylbutazone analogs in man and dog.关于人及犬体内苯丁唑酮类似物的pKa与肾排泄速率之间反比关系的研究。
Am J Med. 1960 Dec;29:1017-33. doi: 10.1016/0002-9343(60)90082-6.
5
Urinary pH.尿液酸碱度
J Urol. 1959 Feb;81(2):339-43. doi: 10.1016/S0022-5347(17)66022-1.
6
Drug therapy. Serum drug concentrations as therapeutic guides.药物治疗。作为治疗指导的血清药物浓度。
N Engl J Med. 1972 Aug 3;287(5):227-31. doi: 10.1056/NEJM197208032870505.
7
Proceedings: The influence of urine pH on the renal excretion of practolol and propranolol.论文集：尿液pH值对醋氨心安和心得安肾排泄的影响
Br J Pharmacol. 1973 Sep;49(1):155P-156P.
8
Preliminary studies on the pharmacology of an antidysrhythmic, Kö 1173, in man.抗心律失常药物Kö 1173在人体中的药理学初步研究。
Br J Pharmacol. 1973 Mar;47(3):674P-675P.
9
The effect of experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide.一种新型抗惊厥药Kö 1173对实验性心律失常的作用及其与苯妥英钠和普鲁卡因胺的比较。
Br J Pharmacol. 1970 May;39(1):183P-184P. doi: 10.1111/j.1476-5381.1970.tb09568.x.
10
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.美西律（Kö 1173）用于室性心律失常的治疗。
Lancet. 1973 Aug 25;2(7826):404-7. doi: 10.1016/s0140-6736(73)92271-x.
Zotero 插件